• Featured Product
  • KD/KO Validated

BRCA2 Polyclonal antibody

BRCA2 Polyclonal Antibody for ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, IHC, ELISA

Conjugate

Unconjugated

Cat no : 19791-1-AP

Synonyms

BRCA2, BRCC2, breast cancer 2, early onset, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1



Product Information

19791-1-AP targets BRCA2 in WB, IHC, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Peptide
Full Name breast cancer 2, early onset
Calculated Molecular Weight 384 kDa
GenBank Accession NumberNM_000059
Gene Symbol BRCA2
Gene ID (NCBI) 675
RRIDAB_10638915
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

BRCA2, also named as FACD and FANCD1, is involved in double-strand break repair and/or homologous recombination. BRCA2 may participate in S phase checkpoint activation. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer (BC) which also called susceptibility to familial breast-ovarian cancer type 2 (BROVCA2).

Protocols

Product Specific Protocols
WB protocol for BRCA2 antibody 19791-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Nucleic Acids Res

LncRNA lnc-RI regulates homologous recombination repair of DNA double-strand breaks by stabilizing RAD51 mRNA as a competitive endogenous RNA.

Authors - Liping Shen
humanWB

Int J Biol Macromol

Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation

Authors - Hong-Yu Tao
humanWB

Elife

LIN37-DREAM prevents DNA end resection and homologous recombination at DNA double-strand breaks in quiescent cells

Authors - Bo-Ruei Chen
humanWB

J Med Chem

Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA

Authors - Limei Ji
humanWB

Pharmacol Res

FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.

Authors - Shi-Qi Wu
humanWB

Mol Cancer

The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy.

Authors - Yan Wang
  • KD Validated